DJIA 17,702.12 -74.00 -0.42%
NASDAQ 4,868.98 -31.91 -0.65%
S&P 500 2,058.49 -9.40 -0.45%
market minute promo

Biogen Idec (NASDAQ: BIIB)

412.05 -10.20 (-2.41%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BIIB $411.61 -2.52%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $423.20
Previous Close $422.24
Daily Range $407.55 - $423.47
52-Week Range $272.02 - $480.18
Market Cap $96.7B
P/E Ratio 34.13
Dividend (Yield) $0.00 (0.0%)
Volume 1,615,655
Average Daily Volume 2,017,055
Current FY EPS $16.88




Drug Makers

Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website:

News & Commentary Rss Feed

Based on This Study, an Alzheimer's Disease Cure Could Be Around the Corner

Alzheimer's drugs have generally fared poorly in clinical trials, but researchers in Australia may have uncovered a groundbreaking and non-invasive method of treating and/or curing this disease.

Stock Market News for April 01, 2015 - Market News

The Top-Performing Biotech Stock During a Sizzling First Quarter

Barclays Raises Biogen Forecasts After Physician Survey

Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog

Healthcare Hedge Fund Orbimed's Top Picks And New Move

Insider Trading Alert - MTEX, BDL And BIIB Traded By Insiders

Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog

Stock Market News for March 30, 2015 - Market News

Bulls, Bears Squaring Off At Biogen

See More BIIB News...

BIIB's Top Competitors

BIIB $412.05 (-2.41%)
Current stock: BIIB
AMGN $156.02 (-2.40%)
Current stock: AMGN
GILD $97.06 (-1.09%)
Current stock: GILD
$0.00 (0.00%)
Current stock: